TrialAllergy2022

First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.

Antonio Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.